Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Howard Williams who wrote (11738)	1/22/2013 11:01:55 AM
From: jm2i123	Respond to of 13111

nice...

To: Howard Williams who wrote (11738)	1/22/2013 11:31:09 AM
From: NTTG	2 Recommendations Read Replies (1) \| Respond to of 13111

Pretty much more of the same old story... - still no evidence that RB selectively partitions into CA cells (nice cartoon, data would help) - They really need to stop showing this combined treatment on remote tumor data as presented...at least normalize the numbers to the time zero values....the intrinsic data scatter (baseline of 8 to over 20...uummm...what are those units for?) is HUGE otherwise - they continue to compare apples and aardvarks (where is the IT Actinomycin D, or 5-FU, or platinum, or..... comparator data?) Oral RB rather than IP RB?????? really...for a drug that is cleared by the liver in first pass metabolism, through a pathway that the company touts as part of their 'safety story' for???? Data geared to sell the story, not tell the story for sure - Finally we get to a study that is reasonably controlled for IP and IT treatment with RB and temozolomide and...alas...no real differences over 14 days. They do know how to do the right study, they just seem to work hard at avoiding it as much as possible

To: Howard Williams who wrote (11738)	1/22/2013 2:05:18 PM
From: pincus	Read Replies (1) \| Respond to of 13111

Am I being too hard on PVCT? One of the slides is titled "Things To Look For." Generally you try not to end a statement with a preposition. I know, small potatoes. However, the first two "things" start with "Currently interacting with..." which means they are both already happening. They are "Things To Watch" or "Things To Follow," and that's if you insist on using the word "things." Either way, that is some really clumsy writing. The next slide is titled "Why Invest In Provectus" which, as written, is a question and demands a question mark.